The efficiency of telerehabilitation in patients with multiple sclerosis

The aim of the study - to evaluate the possibilities and efficacy of telerehabilitation in patients with MS.Цель исследования – оценка возможностей и эффективности телереабилитации у пациентов с РС

РОЛЬ ИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЙ В РАЗВИТИИ РАССЕЯННОГО СКЛЕРОЗА В РЕСПУБЛИКЕ СЕВЕРНАЯ ОСЕТИЯ — АЛАНИЯ

The article describes a research which comprised 220 people, including 110 patients with multiple sclerosis (MS) and 110 control patients who were matched in pairs according to sex, age (± 5 years), ethnicity (all — Ossetians) and place of birth. The authors applied the most convenient and commonly used method of case-control study. The authors revealed a reliable link between multiple sclerosis and infectious mononucleosis or mononucleosis-like diseases, chronic tonsillitis and sinusitis that occurred between the ages of 7 and 15 years as well as varicella that occurred from 0 to 7 years. Под наблюдением находились 220 человек, из них 110 больных рассеянным склерозом (РС) и 110 пациентов контрольной группы, попарно подобранных друг к другу по полу, возрасту (± 5 лет), национальности (все — осетины) и месту рождения. Нами был применён наиболее удобный и часто используемый метод случай-контроль. Была выявлена достоверная связь РС с перенесенными в возрасте от 7 до 15 лет инфекционным мононуклеозом и мононуклеозоподобными заболеваниями, хроническими тонзиллитами и синуситами, а также с перенесенной в возрасте от 0 до 7 лет ветряной оспой.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Supported by F. Hoffmann–La Roche

Nervous system damage in COVID-19 with an emphasis on the management of patients with multiple sclerosis

The main target for COVID-19 is the lung with the development of acute respiratory failure. But the virus also displays tropism to the central nervous, muscle, and immune systems. The paper gives the data available in the literature on nervous system damage and the characteristics of clinical and magnetic resonance imaging manifestations of brain damage in COVID-19. Among the neurological symptoms of COVID-19, there may be stroke, encephalitis, and neuropathy. An account is given of the features of multiple sclerosis patient management during the COVID-19 pandemic depending on the risk of developing coronavirus infection

THE ROLE OF INFECTIOUS DISEASES IN THE DEVELOPMENT OF MULTIPLE SCLEROSIS IN NORTH OSSETIA – ALANIA REPUBLIC

The article describes a research which comprised 220 people, including 110 patients with multiple sclerosis (MS) and 110 control patients who were matched in pairs according to sex, age (± 5 years), ethnicity (all — Ossetians) and place of birth. The authors applied the most convenient and commonly used method of case-control study. The authors revealed a reliable link between multiple sclerosis and infectious mononucleosis or mononucleosis-like diseases, chronic tonsillitis and sinusitis that occurred between the ages of 7 and 15 years as well as varicella that occurred from 0 to 7 years

Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects»

The meeting of experts discussed the clinical and pathophysiological features of secondary progressive multiple sclerosis (MS) (SPMS), clinical trials, and promising treatments for the progressive MS stage, as well as proposals contributing to the improvement of the current state of the problem of SPMS. In particular, the definition of and criteria for SPMS are formulated; the earliest period, when its confirmed progression can be recorded, is stated to be 3 months. The exacerbation-unaffected disability progression confirmed 6 months later may be considered to be more convincing. The introduction of tools for the early assessment of disability progression into routine practice will be able to identify the signs of progression at an earlier stage in order to timely change treatment policy. It is also noted that therapeutic possibilities in establishing secondary progression, especially in the absence of exacerbations, but in maintaining progression, are still insufficient. Certain hopes for slowing the progression in patients with SPMS are associated with the advent of siponimod, a new molecular class of S1P receptor modulators. The confirmed efficiency of siponimod in a large population of patients with SPMS allows the latter to be recommended for its treatment with both persistent disease activity (SPMS with exacerbations) and disability progression without exacerbations (SPMS without exacerbations)

Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS

РОЛЬ ИНФЕКЦИОННЫХ ЗАБОЛЕВАНИЙ В РАЗВИТИИ РАССЕЯННОГО СКЛЕРОЗА В РЕСПУБЛИКЕ СЕВЕРНАЯ ОСЕТИЯ — АЛАНИЯ

The article describes a research which comprised 220 people, including 110 patients with multiple sclerosis (MS) and 110 control patients who were matched in pairs according to sex, age (± 5 years), ethnicity (all — Ossetians) and place of birth. The authors applied the most convenient and commonly used method of case-control study. The authors revealed a reliable link between multiple sclerosis and infectious mononucleosis or mononucleosis-like diseases, chronic tonsillitis and sinusitis that occurred between the ages of 7 and 15 years as well as varicella that occurred from 0 to 7 years. Под наблюдением находились 220 человек, из них 110 больных рассеянным склерозом (РС) и 110 пациентов контрольной группы, попарно подобранных друг к другу по полу, возрасту (± 5 лет), национальности (все — осетины) и месту рождения. Нами был применён наиболее удобный и часто используемый метод случай-контроль. Была выявлена достоверная связь РС с перенесенными в возрасте от 7 до 15 лет инфекционным мононуклеозом и мононуклеозоподобными заболеваниями, хроническими тонзиллитами и синуситами, а также с перенесенной в возрасте от 0 до 7 лет ветряной оспой. </p

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis

The paper presents a detailed algorithm for the treatment and follow-up of patients with recurrent multiple sclerosis and primary progressive multiple sclerosis in the use of ocrelizumab

Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis

Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with MS-modifying drugs (MSMDs) or there is ≥1 exacerbation and corresponding activity signs revealed by MRI during therapy with other MSMDs. A group of expert neurologists from various clinics in Russia, who actively participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects of using the tablets of cladribine registered in Russia in March 2020 for the treatment of patients with HAMS. The paper mentions the groups of patients in whom the drug, an examination before starting a therapy cycle, routes of administration, and dose, and a monitoring scheme during and after treatment cycles are indicated. This drug acts on the principle of selective immunoreconstitution and may occupy an important place in the treatment of HAMS